In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

The organization’s 2026 Breast Cancer Progress Outlook reflects the positive progress in early detection and awareness, showing that breast cancer mortality in the United States has declined 44% ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...

Dave Carey, CEO, Preceptis Medical and Michael Manavukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic program, underscoring continued pharmaceutical interest in genetic medicines ...

PE: What was your experience debuting Trialynx at JP Morgan Healthcare 2026? Schwab: It’s fantastic. This was the culmination ...

On February 1, FDA announced a new pilot program designed to promote the construction of domestic manufacturing sites, along ...

According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...

Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...

The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...